Index removal puts fresh attention on Encompass Health

Encompass Health (EHC) has been removed from the Russell 1000 Dynamic Index, an event that can trigger portfolio adjustments by index-linked funds and spur short term trading and price swings for the stock.

Over the past year Encompass Health’s share price has seen mixed momentum, with a 7 day share price return of 2.25% and a 90 day share price return of 4.31%. The 1 year total shareholder return is down 17.17%, while the 5 year total shareholder return is up 63.58%, so long term investors have still seen gains even as the recent index removal has shifted shorter term sentiment.

If this index change has you reassessing your watchlist, it could be a good moment to broaden your search and check out 41 healthcare AI stocks

With Encompass Health shares down 17.17% over the past year but still up 63.58% over five years, the key question now is whether the recent index removal has left the stock undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 1.7% Overvalued

According to the most followed narrative on Encompass Health, the stock’s fair value is set at $99.17, slightly below the last close of $100.90, which places the shares just above that narrative fair value line.

EHC has demonstrated consistent revenue growth and disciplined expansion through new hospital openings and occupancy improvements. The company benefits from demographic tailwinds, including an aging population and rising demand for post-acute rehabilitation services. Yet what may matter more long term is how effectively providers adapt to outcome-based healthcare frameworks.

Curious what sits behind that valuation gap for Encompass Health? The narrative leans heavily on outcome driven care, margin resilience, and a forward earnings profile that assumes steady, not explosive, expansion. The key is how these moving parts are combined, and which long term profitability path the narrative is really banking on.

Result: Fair Value of $99.17 (OVERVALUED)

However, Encompass Health’s reliance on Medicare and managed care reimbursement, along with any weakening in outcome metrics or readmission trends, could quickly challenge this outcome-focused narrative.

Another View: What Multiples Say About Encompass Health

While the most popular Encompass Health narrative points to a small 1.7% premium to its $99.17 fair value, the market ratio picture looks different. On a P/E of 16.9x, EHC sits below the US Healthcare industry at 25.1x and also below an estimated fair ratio of 21.9x.

That gap suggests investors are paying less for each dollar of earnings than both the sector and the fair ratio imply, even though EHC is slightly expensive compared with a 16.6x peer average. Is the market building in risk, or is this simply a quieter opportunity hiding in plain sight?

Next Steps

Seeing mixed signals around Encompass Health and unsure which side carries more weight? Take a closer look at both the concerns and the potential upside, then decide how that balance fits your own risk tolerance and time horizon with 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Encompass Health?

If Encompass Health has you reassessing where to focus next, broaden your opportunity set with focused stock ideas that match your goals, risk comfort, and time horizon.

• Spot potential turnaround stories early by scanning 22 elite penny stocks with strong financials that already show stronger financial underpinnings than many tiny peers.
• Upgrade the quality of your watchlist by zeroing in on screener containing 19 high quality undiscovered gems that pair solid fundamentals with less crowded ownership.
• Prioritise resilience by focusing on 72 resilient stocks with low risk scores that combine steadier financial profiles with more controlled risk signals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.